title: Pazopanib and liposomal doxorubicin in the treatment of patients with relapsed/refractory epithelial ovarian cancer: a phase Ib study of the Sarah Cannon Research Institute.
abstract: OBJECTIVE
  To investigate the combination of liposomal doxorubicin/pazopanib in advanced relapsed/refractory ovarian cancer.
  
  
  METHODS
  Twenty-two patients received liposomal doxorubicin/pazopanib. Initial doses (liposomal doxorubicin, 40 mg/m2 monthly; pazopanib, 400 mg daily) were too toxic; three subsequent groups received lower doses/altered schedules.
  
  
  RESULTS
  The maximum tolerated doses (MTD) were liposomal doxorubicin, 30 mg/m2, and pazopanib, 400 mg daily. Severe toxicity included neutropenia (18%), rash/desquamation (14%), hypertension (9%), and hand-foot syndrome (9%). Five of the eight patients treated with MTD had grade 3 toxicity during the first two cycles. Dose reductions were frequently required.
  
  
  CONCLUSIONS
  Further development of the liposomal doxorubicin/pazopanib combination is not recommended.
authors.affiliation: Sarah Cannon Research Institute , Nashville, Tennessee , USA ,1.
authors.forename: John D
authors.initials: JD
authors.lastname: Hainsworth
authors.forename: Irfan D
authors.initials: ID
authors.lastname: Firdaus
authors.forename: Chris B
authors.initials: CB
authors.lastname: Earwood
authors.forename: Cynthia C
authors.initials: CC
authors.lastname: Chua
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000077216:Carcinoma, Ovarian Epithelial; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D007191:Indazoles; D008875:Middle Aged; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011092:Polyethylene Glycols / Q000008:administration & dosage; D011743:Pyrimidines / Q000008:administration & dosage; D013449:Sulfonamides / Q000008:administration & dosage
chemical_list: D007191:Indazoles; D011743:Pyrimidines; D013449:Sulfonamides; C506643:liposomal doxorubicin; D011092:Polyethylene Glycols; C516667:pazopanib; D004317:Doxorubicin
keywords: Angiogenesis; Chemotherapy; Ovarian cancer